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http://dx.doi.org/10.1016/j.stemcr.2017.02.016SUMMARYThe isolation or in vitro derivation of many human cell types remains challenging and inefficient. Direct conversion of human plurip-
otent stem cells (hPSCs) by forced expression of transcription factors provides a potential alternative. However, deficient inducible gene
expression in hPSCs has compromised efficiencies of forward programming approaches. We have systematically optimized inducible
gene expression in hPSCs using a dual genomic safe harbor gene-targeting strategy. This approach provides a powerful platform for
the generation of human cell types by forward programming.We report robust and deterministic reprogramming of hPSCs into neurons
and functional skeletal myocytes. Finally, we present a forward programming strategy for rapid and highly efficient generation of human
oligodendrocytes.INTRODUCTION
Despitemajor efforts todevelop robustprotocols for scalable
generation of human cell types from easily accessible and
renewable sources, thedifferentiationofhumanpluripotent
stem cells (hPSCs) into specific cell types often remains
cumbersome, lengthy, and difficult to reproduce.Moreover,
the recapitulation of developmental stages in vitro yields
fetal cells that often do not reach full maturation (Cohen
andMelton, 2011).More recently, forced expression of line-
age-specific master regulators resulting in direct reprogram-
ming of somatic cell types has provided an efficient alterna-
tive todirecteddifferentiation (Huanget al., 2014; Ieda et al.,
2010; Zhou et al., 2008). In particular, the direct conversion
of hPSCs, termed forward programming (Moreau et al.,
2016), combines the advantages of hPSC differentiation
and direct cellular reprogramming, enabling scalable and
rapid generation of human cell types (Zhang et al., 2013).
Currently available forward programming protocols are
largely based on lentiviral transduction of hPSCs, which
results in variegated expression or complete silencing of
transgenes (Darabi et al., 2012; Smith et al., 2008). Addi-
tional purification steps are usually necessary for enriching
the desired cell type. Lentiviral approaches randomly insert
transgenes into the genome bearing the risk of unwanted
interference with the endogenous transcriptional program.
Therefore, refinements to the current forward program-
ming approaches are desirable.Stem C
This is an open access artiAs the result of a systematic effort to optimize gene
expression in hPSCs, we arrived at a robust hPSC forward
programming platform by targeting all components of
the Tet-ON system required for inducible expression
of transcription factors into genomic safe harbor sites
(GSHs) (Sadelain et al., 2012). The Tet-ON system consists
of two components: a constitutively expressed transcrip-
tional activator protein responsive to doxycycline (dox)
(reverse tetracycline transactivator [rtTA]), and an inducible
promoter regulated by rtTA (Tet-responsive element) that
drives expression of the transgene (Baron and Bujard,
2000). Previous GSH-targeting strategies of the Tet-ON
system relied on introducing both elements into the
AAVS1 GSH of hPSCs, either separately (Hockemeyer
et al., 2009), or together (using an all-in-one Tet-ON vector)
(Ordovás et al., 2015; Qian et al., 2014). Compared with
these designs, we reasoned that targeting each of the two el-
ements of the Tet-ON system into a different GSH would
have several advantages: inducible overexpression based
on dual GSH targeting would not be affected by promoter
interferencebetween the two transgenes (BaronandBujard,
2000), while homozygous GSH targeting would maximize
the number of safely targeted transgene copies. Moreover,
the larger cargo capacity in each of the transgenes would
permit increasedflexibility for transgenedesign, thus allow-
ing the insertion of large reprogramming cassettes.
Here we show that an optimized approach based on dual
GSH targeting of Tet-ON-controlled transgenes results inell Reports j Vol. 8 j 803–812 j April 11, 2017 j ª 2017 The Authors. 803
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homogeneous, controllable, and extremely high expres-
sion of inducible transgenes in hPSCs. Application of the
optimized overexpression platform enabled us to develop
rapid and deterministic forward programming protocols
for mature human cell types.RESULTS
Development of an Optimized Inducible Transgene
Overexpression Method by Dual GSH Targeting
To optimize inducible transgene overexpression from
GSHs, we generated human embryonic stem cells (hESCs)
with inducible EGFP (i-EGFP) expression. Initially, we
tested four different designs (Figure S1A). These comprised
two all-in-one targeting constructs in which both rtTA and
i-EGFP expression cassettes (third-generation Tet-ON sys-
tem) were inserted into the same allele of the AAVS1 GSH
locus. In these constructs, the rtTA expression was under
the control of either an EF1a or CAG promoter. The other
two transgene designs were based on spatial separation of
the activator and responder into two distinct GSHs (Fig-
ure S1A). For this purpose, we sequentially targeted the
rtTA cassette into the human ROSA26 GSH (Bertero et al.,
2016) and an i-EGFP transgene into the AAVS1 GSH (Fig-
ures 1A and S1A–S1E) (Hockemeyer et al., 2009). Robust
and homogeneous inducible transgene expression was
achieved only when the dual GSH approach and a CAG
promoter for rtTA expression was used (Figure S1A). Impor-
tantly, the dual GSH-targeting approach was highly effi-
cient (Table S1), and did not affect hESC self-renewal or
differentiation (Figures 1H–1K).
Using the CAG promoter-based dual GSH-targeting
approach, we selected clonal lines that carried either oneFigure 1. Development of an Optimized Inducible Gene Overexpr
(A) Workflow for targeting the hROSA26 and AAVS1 loci with the Tet-
D10A nickase mutant Cas9 endonuclease; ZFN, zinc-finger nucleas
element.
(B) Schematic of the four outcomes following generation of dual GSH
on the number of successfully targeted alleles of the hROSA26 and A
(C) Detection of the rtTA protein by western blot in heterozygous (HE
targeting results in increased rtTA protein expression. hESCs with rand
hESCs are shown as positive and negative reference. a-Tubulin, loadi
(D) Median fluorescent intensity (MFI) of EGFP expression in the va
analyzed by flow cytometry in non-induced conditions (CTR) or follow
included for comparison. Statistical analysis of dox-treated groups d
clones (each data point, n = 1–5, represents a clonal line; mean ±
****p < 0.0001).
(E) Flow cytometry of EGFP OPTi-OX hESCs after 5 days of dox treatm
(F and G) EGFP induction and rescue kinetics (F) and dox dose-respo
biological replicates; mean ± SEM; all values normalized to the maxim
(H–K) Immunocytochemistry (ICC) for lineage-specific markers in und
the germ layers.or two copies of each of the transgenes (Figure 1B), and
observed that homozygous targeting of both elements
allowed maximal inducible overexpression (Figures 1C,
1D, S1E, and S1F). Under these conditions, EGFP expres-
sion was induced homogeneously in all cells, consistent
across multiple clones, and more than 50-fold higher
compared with EGFP expression via the strong constitutive
CAG promoter (Figures 1D, 1E, S1E, and S1F). Maximal
EGFP levels were reached approximately 4 days after induc-
tion, and expression was quickly reversed upon dox with-
drawal (Figure 1F). Moreover, EGFP expression could be
titrated by adjusting the dose of dox (Figure 1G). I-EGFP
expression was highly efficient in hESCs (Figures 1E and
1H), and during germ layer differentiation (Figures 1I–1K
and S1G). There was no detectable background expression
of EGFP in the absence of dox (Figures 1D, 1E, and S1G).
Taken together, these results established that homozy-
gous dual GSH targeting of the Tet-ON system is a powerful
strategy for homogeneous and controllable expression of
inducible transgenes in hPSCs and their derivatives. We
will refer to this platform as ‘‘OPTi-OX’’ (optimized induc-
ible overexpression).
Human Induced Neurons
To test the applicability of the OPTi-OX platform for for-
ward programming of hPSCs intomature cell types, we first
chose to generate excitatory cortical neurons, as previous
studies demonstrated that these can be readily derived
by lentiviral overexpression of pro-neuronal transcription
factors in hPSCs (Zhang et al., 2013).
To this end, we generated NGN2 OPTi-OX hPSCs (Fig-
ure 2A; Table S1), and treated them with dox in chemically
defined neuronal culture medium (Zhang et al., 2013).
Induction of NGN2 expression (Figure S2A) resulted inession System
ON system in hPSCs for inducible EGFP expression (i-EGFP). Cas9n,
es; rtTA, reverse tetracycline transactivator; TRE, Tet-responsive
-targeted inducible EGFP hESCs: clonal lines were categorized based
AVS1 loci.
T) and homozygous (HOM) hROSA26-CAG-rtTA hESCs. Homozygous
om integration of a second-generation rtTA (M2-rtTA) and wild-type
ng control.
rious dual GSH-targeted i-EGFP hESCs described in (B). Cells were
ing 5 days of dox. AAVS1-CAG-EGFP and wild-type (WT) hESCs were
emonstrated that EGFP levels were highest in double-homozygous
SEM; one-way ANOVA with post hoc Dunnett’s test; **p < 0.01,
ent. Non-induced cells were included as negative control.
nse (G) in EGFP OPTi-OX hESCs detected by flow cytometry (n = 2
um fluorescence intensity after 5 days of dox).
ifferentiated EGFP OPTi-OX hESCs and following differentiation into
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Figure 2. Forward Programming of hPSCs into Neurons
(A) Experimental approach for conversion of NGN2 OPTi-OX hPSCs into i-Neurons.
(B) Time course of i-Neuron generation from hESCs by qPCR demonstrating the expression pattern of pluripotency factors (OCT4
and NANOG), pan-neuronal (MAP2 and SYP), forebrain (BRN2, FOXG1), and glutamatergic neuronal marker genes (VGlut2, GRIA4) (n = 3
biological replicates; mean ± SEM; relative to PBGD and normalized to pluripotency).
(C) Phase contrast images illustrating the morphological changes during i-Neuron generation (a corresponding time-lapse is shown in
Movie S1).
(D) ICC for the pan-neuronal marker proteins bIII-tubulin (TUBB3) and microtubule-associated protein 2 (MAP2) during the generation of
i-Neurons.
(E) Quantification of bIII-tubulin-positive neuronal cells by ICC after 1 week of induction. Undifferentiated cells were used as negative
control, and numbers are reported for i-Neuron generation in newly isolated NGN2 OPTi-OX hESCs and after 25 passages.
(F and G) ICC for neuronal markers in i-Neurons 14 days after induction.downregulation of pluripotency factors and initiation of
the neuronal transcriptional program (Figure 2B). Dox-
treated cells extended neuronal processes as early as
3 days post induction. After 1 week, all cells displayed a
neuronal morphology and expressed the pan-neuronal
markers bIII-tubulin and MAP2 (Figures 2C–2E and Movie
S1). At this stage, induced neurons (i-Neurons) showed
strong expression of forebrain markers BRN2 and FOXG1,
and of glutamatergic neuronal genes GRIA4, VGLUT1,
and VGLUT2 (Figures 2B and 2F), indicative of an
excitatory cortical neuronal identity of the forward-pro-
grammed cells, consistent with previous reports (Zhang
et al., 2013). Short pulses of dox treatment for 4 days or
longer sufficed for complete conversion, and converted
cells did not rely on continuous transgene expression (Fig-
ures S2B and S2C). Importantly, we did not observe any
reduction in the efficiency of generating i-Neurons over
extended culture periods of the inducible hESCs (>25 pas-
sages, Figure 2E). Finally, we confirmed the applicability
of the NGN2 OPTi-OX system in hiPSCs (Figure 2G).806 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017Collectively, these results demonstrated that OPTi-OX en-
ables robust and rapid forward programming of hPSCs
into cortical neurons.
Human Induced Skeletal Myocytes
To further explore the potential of OPTi-OX for forward
programming of hPSCs, we focused on generating human
skeletal myocytes. Existing protocols for the directed differ-
entiation of skeletal myocytes from hPSCs are difficult,
time consuming, and result in low and variable yields
(Chal et al., 2015). On the other hand, myogenic transdif-
ferentiation has been achieved by overexpressing the
transcription factor MYOD1 in somatic cell types, but the
ability of hPSCs to undergo MYOD1-induced forward
programming is a matter of debate (Abujarour et al.,
2014; Albini et al., 2013; Tanaka et al., 2013).
We therefore generatedMYOD1OPTi-OX hPSCs (Figures
3A and 3B and Table S1). However, induction of MYOD1
expression following dox treatment resulted in cell death
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(data not shown). These findings demonstrated that
MYOD1 overexpression alone was not sufficient to drive
myogenesis in hPSCs, in agreement with the postulated ex-
istence of epigenetic barriers preventing forcedmyogenesis
(Albini et al., 2013).
Cellular reprogramming strategies can be enhanced by
combining transcription factor overexpression with extra-
cellular signaling cues (Bar-Nur et al., 2014). We conducted
a systematic screen for pro-myogenic factors by modu-
lating key signaling cascades that are implicated in primi-
tive streak formation, somitogenesis, and myogenesis
(Figure S3A). We found that the addition of all-trans reti-
noic acid (RA) in conjunctionwithMYOD1 overexpression
was sufficient for rapid and deterministic conversion of
hPSCs into myogenin and myosin heavy chain double-
positive myocytes after 5 days of induction (Figures 3C
and S3A). The effect of RA was concentration dependent
(data not shown), and mediated at least in part through
the receptor isoforms RARa and RARb (Figures S3B
and S3C).
Following minor optimization of the culture condi-
tions (see the Supplemental Experimental Procedures), we
arrived at a protocol resulting in nearly pure induced skel-
etalmyocytes (i-Myocytes). Reprogrammed cells developed
typical spindle-like, elongated morphology, underwent
extensive cell fusion, and exhibited strong and homoge-
neous myogenic marker expression on mRNA and protein
levels (Figures 3D–3H, S3D, and S3E; Movie S2). Further-
more, the addition of nanomolar concentrations of acetyl-
choline (ACh) or the selective ACh-receptor agonist carba-
chol resulted in muscle fiber contraction, demonstrating
the functionality of the i-Myocytes (Movie S3). Similar
results were obtained with i-Myocytes generated from
MYOD1 OPTi-OX hiPSCs (Figure S3F). Importantly, induc-
tion efficiency did not decrease over extended culture pe-Figure 3. Forward Programming of hPSCs into Skeletal Myocytes
(A) Experimental approach for rapid single-step conversion of MYO
treatment with dox and RA.
(B) Representative ICC for MYOD1 before (CTR) and after induction w
expression, paralleled by downregulation of the pluripotency factors
(C) Effect of RA onmyocyte forward programming compared with other
the entire signaling molecule screen).
(D) qPCR of the temporal expression pattern of pluripotency factors (
(n = 3 biological replicates, mean ± SEM; relative to PBGD and norma
(E and F) ICC for skeletal myocyte markers in i-Myocytes.
(G and H) Quantification of MHC-positive cells by flow cytometry 10
control, and figures are reported for i-Myocyte generation in newl
50 passages (+P50) (n = 3 biological replicates; mean ± SEM).
(I) qPCR for total MYOD1, endogenous MYOD1, and MYOG 2 days po
replicates; mean ± SEM).
(J) ICC for myogenin andmyosin heavy chain following 5 days of induc
cell clusters appeared when the dox concentration was lowered to 0.1
myocyte cell populations.
808 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017riods (>50 passages, Figure 3H), thus demonstrating the
robustness and reproducibility of this method. Finally, we
noted that the levels of theMYOD1 transgene following in-
duction positively correlated with conversion efficiency
(Figures 3I and 3J), which highlights the importance of a
robust gene-delivery method. In conclusion, these data
demonstrated that the OPTi-OX platform enables robust
and rapid forward programming of hPSCs into skeletal
myocytes.
Human Induced Oligodendrocytes
Encouraged by our results deriving neurons and myocytes,
we sought to utilize the same overexpression system to
develop a forward programming protocol for oligodendro-
cytes. Oligodendrocytes are of critical importance for CNS
function and their loss or dysfunction plays a key role in
many neurological diseases. Unlike neurons (Zhang et al.,
2013), protocols for efficient generation of human oligo-
dendrocytes from renewable sources remain an unmet
need: currently available hPSC differentiation protocols
are extremely long (up to 200 days) and yield heteroge-
neous cell populations (Douvaras et al., 2014; Stacpoole
et al., 2013; Wang et al., 2013).
We generated OPTi-OX hPSCs bearing inducible SOX10
either alone or in combination with OLIG2 in the form
of a polycistronic expression cassette (Figure 4A). Although
cells induced with SOX10 alone robustly expressed
the oligodendrocyte precursor (OPC) marker O4 after
10 days of induction, these cells failed to differentiate into
myelin-expressing cells and died (Figure 4A). In contrast,
the OLIG2-SOX10 overexpressing cells progressed from
an O4-positive progenitor stage into a mature CNP/MBP-
positive phenotype after 20 days of induction (Figure 4A).
Moreover, gene expression analysis confirmed that
OLIG2-SOX10OPTi-OXhPSCs induced in oligodendrocyteD1 OPTi-OX hPSCs into skeletal myocytes (i-Myocytes) following
ith dox. This demonstrates homogeneous induction of transgene
NANOG and OCT4.
wise identical control (CTR) induction conditions (see Figure S2B for
top panel) and myocyte marker genes during i-Myocyte generation
lized to pluripotency).
days after induction. Undifferentiated cells were used as negative
y isolated MYOD1 OPTi-OX hESCs, or in the same cells following
st induction with different dox concentrations (n = 3 biological
tion with different dox concentrations. Non-converted, proliferative
25 mg/mL. Further reduction of dox resulted in an increase in non-
A
G
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Figure 4. Forward Programming of hPSCs into Oligodendrocytes
(A) ICC for inducible transgenes after 1 day of induction (left column), the OPC marker O4 after 10 days (middle), and the oligodendrocyte
markers CNP and MBP after 20 days (right).
(B) Experimental approach for rapid conversion of OLIG2-SOX10 OPTi-OX hPSCs into the oligodendrocyte lineage cells (i-OPCs and i-OLs).
(C and D) Characterization of i-OPCs by ICC for OPC surface markers (A2B5, O4, PDGFRA).
(legend continued on next page)
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medium (Douvaras et al., 2014) supplemented with the
mitogens PDGFaa and FGF2 first passed through an OPC-
like stage, during which they remained proliferative and
co-expressed typical OPCmarkers (Figures 4B–4F). Remark-
ably, following withdrawal of mitogens, i-OPCs differenti-
ated into mature oligodendrocytes, expressing the typical
myelin-associated proteins (Figures 4G–4M).DISCUSSION
OPTi-OX is the result of a systematic effort to optimize gene
expression in hPSCs. It relies on a dual GSH-targeting strat-
egy for the Tet-ON system, overcoming the limitations of
viral-mediated transgene delivery forward programming
protocols (Abujarour et al., 2014; Darabi et al., 2012; Zhang
et al., 2013) and allows stronger andmore controlled trans-
gene overexpression compared with previous targeting ap-
proaches (González et al., 2014; Hockemeyer et al., 2009;
Ordovás et al., 2015). Table S2 compares the gene-delivery
methods that have been used for transcription factor
expression in different hPSC forward programming ap-
proaches. Moreover, site-specific insertion of the two com-
ponents of the inducible gene expression system mini-
mizes genomic off-target effects and together with the
chemically defined medium compositions enhances the
reproducibility of the protocols.
The functionality of our platform is exemplified through
the production of several cell types. First, we show that
NGN2 andMYOD1OPTi-OXhPSCs can be used as an inex-
haustible source for highly scalable, rapid, single-step, vi-
rus-free, chemically defined, fully reproducible, and deter-
ministic generation of i-Neurons and i-Myocytes.
Finally, we successfully applied the OPTi-OX platform to
develop a forward programming protocol for generating
human oligodendrocytes. Recent studies demonstrated
that forced expression of transcription factors allows direct
conversion of rodent fibroblasts (Najm et al., 2013; Yang
et al., 2013), and primary human fetal neural stem cells
(Wang et al., 2014) into OPCs, but the reprogramming of(E) Characterization of i-OPCs by qPCR compared with hPSCs (PLURI)
included i-Neurons as negative control (n = 3 biological replicates; me
Dunnett’s test; *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001
(F) Immunostaining for BrdU (left panel) and quantification of BrdU-
and concomitant BrdU-pulses (n = 3 biological replicates; mean ± SE
(G) qPCR of the temporal expression pattern of genes encoding for the
i-OL generation. OLIG2-SOX10 OPTi-OX hPSCs were induced in oligoden
of induction, mitogens were withdrawn to enable terminal differentia
PBGD and normalized to pluripotency).
(H) Quantification of CNP and PLP expressing i-OLs derived from OLI
ferentiated cells were used as negative control, and figures are repo
passages (+P50).
(I–M) ICC providing an overview (I) and high-magnifications (J–M) o
810 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017renewable human cell sources into oligodendrocytes has
not been reported. While i-OPCs undergo the expected
morphological changes, and express mature markers in
monocultures in vitro, further characterization of the cells
using co-culture models and transplantation into myelin-
deficient mutants is needed.
Human oligodendrocytes are of considerable interest for
several applications. The efficiency and speed of the pre-
sented forward programming system will enable high-
throughput drug screens and toxicology testing, in vitro
modeling of hereditary leukodystrophies, and the devel-
opment of cell-transplantation strategies (Goldman et al.,
2012).
Transcription factor combinations for direct cellular
reprogramming into many cell types of clinical interest
are now available, including cardiomyocytes (Ieda et al.,
2010), pancreatic b cells (Zhou et al., 2008), and hepato-
cytes (Huang et al., 2014). We anticipate that the OPTi-
OX platform will be applicable for the generation of
many other cell types. Overall, the presented method can
provide the basis for inexhaustible, high-throughput, ho-
mogeneous, and large-scale manufacturing of many hu-
man cell types.EXPERIMENTAL PROCEDURES
Gene Targeting
Targeting of the hROSA26 and AAVS1 locus was performed as
described recently (Bertero et al., 2016). Targeting of the hROSA26
locus was done by nucleofection. Neomycin-resistant colonies
were picked and screened by genotyping. Correctly hROSA26-
rtTA-targeted cloneswere subsequently targetedwith the inducible
transgene cassette in the AAVS1 locus by lipofection. Resulting
puromycin-resistant colonies were picked and re-analyzed by
genotyping.
Inducible Transgene Expression and Forward
Programming
Inducible overexpression was performed with dual GSH-targeted
OPTi-OXhPSCs. Expression of inducible transgenes was prompted. As transcription of CSPG4 (NG2) was also detected in hPSCs, we
an ± SEM; all values relative to PBGD; one-way ANOVA with post hoc
; ns, p > 0.05).
positive cells following three serial passages of i-OPCs every 4 days
M; P, passage).
myelin-associated proteins (CNP, MAG, MBP, MOG, and PLP) during
drocyte medium supplemented with PDGFaa and FGF2. After 1 week
tion (n = 3 biological replicates; mean ± SEM; all values relative to
G2-SOX10 OPTi-OX hPSCs after 20 days of induction by ICC. Undif-
rted for newly isolated OLIG2-SOX10 OPTi-OX hPSCs and after 50
f mature pre-myelinating oligodendrocytes.
by adding dox to the culture medium. For forward programming
into neurons, skeletal myocytes, and oligodendrocytes, standard
medium conditions for the derivation of the respective cell types
were used. Gene and protein expression analysis was performed
as described recently (Bertero et al., 2016). Please refer to the Sup-
plemental Experimental Procedures for details on culture condi-
tions and analysis techniques.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, two tables, and three movies and can
be found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2017.02.016.
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